Ensifentrine is a first-in-class, selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, indicated for the maintenance treatment of chronic obstructive pulmonary… Read more
Ensifentrine is a first-in-class, selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. By modulating intracellular cyclic nucleotide levels, this therapeutic agent provides combined bronchodilatory and anti-inflammatory effects, helping to improve airflow and manage respiratory symptoms. This category provides essential reference materials, including the API, synthetic impurities, metabolites, and stable isotope-labelled compounds, designed to support rigorous analytical testing. Pharmaceutical laboratories rely on these high-purity standards and labelled analogues for precise impurity profiling, method validation, and the accurate quantification of Ensifentrine in complex drug formulations. By using these specialized materials, researchers and quality control professionals can ensure consistent product quality, verify method performance, and maintain regulatory compliance throughout the pharmaceutical development and manufacturing lifecycle.